Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2023
Archives
Opioid use for chronic pain: Part 2
Norm Buckley and Jason Busse from the Michael G. DeGroote Institute for Pain Research & Care in Canada probe the effectiveness of opioid use in Canada as a treatment for chronic noncancer pain.
Developing novel treatments for childhood solid cancers
With a particular focus on glioma, Dr Peter J Houghton from Greehey Children’s Cancer Research Institute outlines the barriers that have hindered the development of effective therapies for childhood solid cancers.
Classification of rare diseases: The case of the ultra-and hyper-rare
Dr C. I. Edvard Smith, Dr Daniel W. Hagey and Dr Rula Zain, from the Karolinska Institutet in Sweden, note that there is an almost infinite number of unique diseases, contributing to the challenges with the classification of rare diseases.
Drug repositioning without the gene expression of disease cells treated with drugs
Y-h. Taguchi, Professor at the Department of Physics, Chuo University in Japan, provides comments on drug repositioning without the gene expression of disease cells treated with various drugs.
Investigating OTC drugs: Are over-the-counter drugs an under-appreciated toxic danger?
Contrary to popular belief, OTC drugs are not harmless. Understanding the effects and dangers of OCT abuse and misuse is key to public safety, here UC Davis provides everything you need to know.
Understanding thermolabile protecting groups for nucleic acid-based drugs
Serge L. Beaucage investigates thermolabile protecting groups for the amine functions of purine and pyrimidine deoxyribonucleosides for the development and implementation of synthetic DNA sequences as nucleic acid-based drugs.
The global regulatory landscape for psychedelic drugs
Jessica Riggleman, Owner of Raeco, LLC, examines the global regulatory landscape for psychedelic drugs, with a particular focus on Schedule I classification.
HIV therapeutic targets: Basic virology to the discovery of antiretroviral drugs
Do we need new antiretroviral drugs to treat HIV infection, and if so, what are the promising targets? Dr Eric O. Freed, Director of the HIV Dynamics and Replication Program at the National Cancer Institute in Frederick, Maryland, discusses these questions.
Beyond amyloid: What’s next for Alzheimers disease therapeutics?
Bradlee Heckmann, PhD, from USF Health Neuroscience Institute, Byrd Alzheimer’s Center & Asha Therapeutics, in this discussion goes beyond amyloid, asking what’s next for Alzheimer’s Disease therapeutics.
RR-TB treatments, testing bedaquiline and injectable kanamycin
Here, Professor Andre Nunn from Medical Research Council Clinical Trials Unit at UCL, explores tuberculosis with a focus on RR-TB treatments (rifampicin-resistant) and their drug combinations.
Psychedelic therapies are returning to psychiatry
Professor Erika Dyck, Canada Research Chair in History of Health & Social Justice at the University of Saskatchewan, looks to psychedelic therapies outside the pharmaceutical industry to aid mental illness.
Understanding amyloid beta and Alzheimer’s disease: the key to helping AD patients
Efforts to prevent or treat Alzheimer’s Disease (AD) by targeting Amyloid beta (Aβ) assemblies should be continued, but the strategies should be altered dramatically.
Wicked-Schisto: The wicked public health problem of Schistosomiasis and the interdisciplinary research helping to...
Poppy Lamberton, Professor of Global Health at the University of Glasgow, is leading an interdisciplinary team aiming to identify cost-effective, sustainable interventions for schistosomiasis, a devastating neglected tropical disease.
Brain health conditions: Excellence in psychedelic treatments
Psychedelic treatments open up an unparalleled window of opportunity, but we need to get ready for their roll-out.
The fentanyl crisis: Death at the end of the rainbow
Chelsea Unkel, Ryan Hogans, & Pamela Lein from the University of California, Davis, analyse the fentanyl crisis responsible for increases in drug overdose across the US.
Evaluating a novel treatment for opioid use disorder based on dual-brain psychology and photobiomodulation
Dr. Fredric Schiffer, founder and CEO of MindLight, LLC, looks at treatments for opioid use disorder based on Dual-Brain Psychology and photobiomodulation. Dr. Schiffer is also a part-time assistant professor in psychiatry at Harvard Medical School.
Alzheimer’s drug slows memory decline in phase 3 trial
Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.
